hotspot -WSS

hotspot

author：fashion 2025-09-29 22:50:30 - browse：61

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Eight reasons why you should get an updated Covid vaccine

WSS

This gene therapy has record $4.25 million price. It's saved children.

Eight reasons why you should get an updated Covid vaccine

6 surprising facts about sugar

Biotech investment managers search for lucrative opportunities

How doctors and nurses shape Google's AI

A revolution in caring for preterm infants

knowledge

hotspot

entertainment

Virginia high school admissions case could be legal follow

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Medical leaders decry Supreme Court decision on affirmative action

How doctors and nurses shape Google's AI

Apple is now the first public company to be valued at $3 trillion

European regulators consider appeal over Amylyx ALS drug

Apple is now the first public company to be valued at $3 trillion

Cancer, immunology, HIV research ensnared in fetal tissue politics

Moonlake's readout produced a cash windfall. Risks remain

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

How doctors and nurses shape Google's AI

Chinese researcher claims birth of first gene

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Yancopoulos of Regeneron works to expand Dupixent success

Pregnancy ages women, but effects reverse after delivery

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

leisure time

knowledge

entertainment

entertainment